Pfizer stock currently has a 5.9% dividend yield, making it an attractive target for income investors.Pfizer (PFE -0.60%) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the dividend yield up to nearly 6%. Is this your chance to secure a generous income stream of dividends?Earn $1,000 in dividend income with this strategyWith the current dividend yield at 5.9%, you would need to invest ...

These two blue chip dividend stocks are top buys right now.Dividends may be boring but are essential to building a well-balanced portfolio. After all, dividend payments have accounted for approximately 85% of the S&P 500's total returns since 1960, per a report by Hartford Funds.Which dividend stocks are worth buying in the current market? Telecom giant AT&T (T 0.18%) and pharmaceutical titan Pfizer (PFE 1.80%) scan as incredible bargains for long-term, income-oriented investors. Read on to find out more ab ...

Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years.After steadily raising its payout by 163% over the past 15 years, Pfizer (PFE 1.80%) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The company is a pharmaceutical giant with many parts moving in different directions. Some of its blockbusters are losing market exclusivity, but it's also developing plenty of new drugs to take t ...

Financial Performance - Total revenues for the three months ended March 31, 2024, were $14,879 million, a decrease of 19% compared to $18,486 million for the same period in 2023[11]. - Product revenues for the same period were $12,443 million, down from $16,221 million, reflecting a decline of 23%[11]. - Alliance revenues increased to $2,172 million, compared to $2,060 million, marking a growth of 5%[11]. - Net income attributable to Pfizer Inc. common shareholders for the three months ended March 31, 2024, was $3,115 million, down from $5,543 million, a decrease of 44%[11]. - Earnings per share (EPS) for the three months ended March 31, 2024, were $0.55, compared to $0.98 for the same period in 2023, a decline of 44%[11]. - The company reported income from continuing operations before tax provision of $3,421 million, down from $6,270 million, a decrease of 45%[11]. - Comprehensive income attributable to Pfizer Inc. for the three months ended March 31, 2024, was $3,319 million, down from $5,558 million for the same period in 2023[13]. - Net income for the three months ended March 31, 2024, was $3,123 million, a decrease of 44% compared to $5,556 million for the same period in 2023[13]. Expenses and Costs - Research and development expenses for the quarter were $2,493 million, slightly down from $2,505 million in the prior year[11]. - Cost of sales for the quarter was $3,379 million, a decrease from $4,886 million, reflecting a reduction of 31%[11]. - Amortization of intangible assets for the quarter was $1,308 million, up from $1,103 million, an increase of 19%[11]. - The company incurred restructuring charges and certain acquisition-related costs amounting to $102 million, compared to $9 million in the same period last year[11]. - The company reported depreciation and amortization expenses of $1,736 million for the three months ended March 31, 2024, an increase from $1,487 million in the prior year[18]. Assets and Liabilities - Total current assets decreased to $42,415 million as of March 31, 2024, down from $43,333 million at December 31, 2023[14]. - Total liabilities decreased to $128,537 million as of March 31, 2024, compared to $137,213 million at December 31, 2023[14]. - Cash and cash equivalents significantly decreased to $719 million from $2,853 million at December 31, 2023[14]. - Trade accounts receivable decreased to $10,989 million as of March 31, 2024, from $11,566 million at December 31, 2023[14]. - Total equity attributable to Pfizer Inc. shareholders increased to $92,282 million as of March 31, 2024, from $89,014 million at December 31, 2023[14]. - The company reported a decrease in inventories to $10,892 million as of March 31, 2024, compared to $10,189 million at December 31, 2023[14]. - Short-term borrowings decreased to $8,232 million as of March 31, 2024, from $10,350 million at December 31, 2023[14]. - The company’s long-term debt remained relatively stable at $61,307 million as of March 31, 2024, compared to $61,538 million at December 31, 2023[14]. Cash Flow - Net cash provided by operating activities for the three months ended March 31, 2024, was $1,090 million, down from $1,212 million in the same period last year[18]. - The company reported a net cash increase from investing activities of $1,732 million for the three months ended March 31, 2024, compared to $3,315 million in the prior year[18]. - Cash dividends paid during the three months ended March 31, 2024, were $2,372 million, compared to $2,303 million in the same period last year[18]. Acquisitions and Investments - Pfizer completed the acquisition of Seagen for a total consideration of $44.2 billion, with the acquisition date on December 14, 2023[26]. - The provisional amount recognized for identifiable intangible assets from the Seagen acquisition was $7,970 million, subject to adjustments[27]. - Goodwill recognized from the Seagen acquisition was $17,650 million after measurement period adjustments[28]. - Pfizer sold approximately 30% of its investment in Haleon for total consideration of $3.5 billion, recognizing a gain of $150 million in the first quarter of 2024[31]. - The carrying value of Pfizer's investment in Haleon decreased to $7,922 million as of March 31, 2024, down from $10,980 million as of April 2, 2023[35]. Legal Proceedings - The company is involved in various legal proceedings, including patent litigation, which could result in significant revenue loss if adverse outcomes occur[87]. - Pfizer is currently facing challenges to its patent rights in multiple jurisdictions, which could impact the market entry of generic products[88]. - The company has settled several patent-infringement actions related to Xeljanz with generic manufacturers, with ongoing litigation against Sinotherapeutics[90]. - Several generic companies have filed ANDAs with the FDA for Mektovi, challenging multiple patents expiring between 2030 and 2033, leading to patent infringement actions by the company[91]. - In June 2023, the company initiated patent infringement actions against Teva Pharmaceuticals regarding Mektovi, asserting the validity of three patents[91]. - Multiple generic companies have filed ANDAs for tafamidis and tafamidis meglumine, prompting the company and Scripps Research Institute to file patent infringement actions in August 2023[92]. - The company is involved in various legal proceedings regarding Comirnaty, including multiple complaints alleging patent infringement filed by Alnylam and Moderna, with ongoing litigation in both U.S. and European courts[94][95]. Revenue Breakdown - Biopharma segment revenues for Q1 2024 were $14,604 million, a decrease of 19% from $18,173 million in Q1 2023[129]. - U.S. revenues increased by 9% to $9,514 million in Q1 2024, compared to $8,711 million in Q1 2023[131]. - Revenues from international developed markets fell by 43% to $3,198 million, while emerging markets dropped by 48% to $2,167 million[131]. - Significant product revenues included $2,035 million from Paxlovid in Q1 2024, down from $4,069 million in Q1 2023[133]. - Oncology division revenue increased to $2,572 million in Q1 2024 from $1,983 million in Q1 2023, marking a growth of about 30%[136]. - Revenue from Oxbryta for sickle cell disease rose to $84 million in Q1 2024, up from $71 million in Q1 2023, reflecting a growth of about 18%[136]. - Revenue from Cibinqo for atopic dermatitis increased to $42 million in Q1 2024, compared to $16 million in Q1 2023, showing a significant growth of 163%[136]. - Total royalty revenues increased to $263 million in Q1 2024 from $204 million in Q1 2023, representing a growth of approximately 29%[136].

Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.The lawsuits were filed in state courts across the country, but the agreements don’t completely resolve Pfizer’s exposure to the claims linking Zantac and cancer, according to Bloomberg News.Terms of the settlements were not disclosed. The Post has sought comment from Pfizer. 3 Pfizer has reportedly agreed to settle more tha ...

ekapol/iStock via Getty Images Written by Sam Kovacs. Introduction Everyone says they want to buy low and sell high, but for some reason they forget to do so. Pfizer Inc. (NYSE:PFE) stock has been on a wild ride these past 4 years. Had you had the foresight to bet on Pfizer in 2020 during the first few months of the pandemic, you would have enjoyed 50% returns within a year or so. The only caveat is that you would have had to have sold your shares at the top, or close enough to the top to have held on t ...

Key PointsPfizer continues to see COVID-19 revenues plummet as Paxlovid revenues dropped 50% and Comirnaty revenues dropped 88% YoY.Despite a 19.5% drop in YoY Q1 2024 revenues, its non-COVID drugs added $12.5 billion to quarterly revenues, and oncology product revenues rose 11% YoY.Pfizer raised its 2024 EPS estimates to $2.15 to $2.35, up from its previous forecast of $2.05 to $2.24 versus $2.21 consensus estimates.5 stocks we like better than PfizerBiopharma giant Pfizer Inc. NYSE: PFE has given back all ...

A double beat on earnings, plus raised bottom-line guidance, made the company a hot item on Hump Day.Pfizer (PFE 6.09%) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on analyst estimates and provide encouraging guidance. The company's share price ended the day more than 6% higher, in contrast to the 0.3% slump of the S&P 500 index.The Covid effect not as damaging as fearedFor its firs ...

Financial Data and Key Metrics Changes - Total company revenues for Q1 2024 were $14.9 billion, reflecting an operational decline of $3.5 billion or 19% compared to the previous year, primarily due to a declining COVID environment [21][20] - Adjusted gross margin improved by 530 basis points to 79.6% compared to Q1 of last year, driven by lower sales volume of Comirnaty, a product return adjustment for Paxlovid, and strong cost management [22][23] - Adjusted diluted EPS was $0.82, exceeding expectations due to favorable gross margin performance and strong cost management [24] Business Line Data and Key Metrics Changes - Oncology revenues grew 19% operationally year-over-year, driven by the acquisition of products from Seagen and strong launches of Padcev and Xtandi [10][11] - Vyndaqel and Eliquis contributed positively to revenue growth, while Ibrance and Sulperazon saw lower demand, particularly in China [21][22] - Abrysvo showed potential for significant market expansion, with positive results from the Phase 3 MONeT trial for RSV vaccine in adults [13][16] Market Data and Key Metrics Changes - The company reached over 119 million patients with its medicines and vaccines in the first quarter [8] - The adult vaccine market is contracting due to fewer eligible adults aged 65 and older, impacting overall market dynamics [116] - The pediatric segment saw a significant increase in market share, with Prevnar achieving 80% share following the launch of PCV 15 [116][120] Company Strategy and Development Direction - The company is focused on five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value [8][18] - The goal is to double the number of patients treated with innovative cancer medicines by 2030 and increase the number of blockbuster medicines in the portfolio [11] - The company is committed to de-levering its capital structure while maintaining and growing its dividend over time [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2024, highlighting strong execution in commercial operations and a focus on protecting and growing core brands [18][20] - The company raised its adjusted EPS guidance for 2024 by $0.10, reflecting confidence in operational strength and cost savings [28][29] - Management acknowledged the challenges posed by the declining COVID environment but emphasized the ongoing significance of COVID products to revenue and cash flow [21][20] Other Important Information - The company recorded a favorable product return adjustment for Paxlovid, contributing $0.11 to earnings per share [25] - The integration of Seagen is expected to enhance commercial leverage and drive growth in oncology products [90][92] - The company is exploring opportunities in the obesity market, with multiple agents in clinical trials [138] Q&A Session Summary Question: What drove the downtick in RSV vaccine sales? - Management noted that the RSV vaccination market follows a seasonal trend, with a peak in January followed by a decline [33][34] Question: Any potential impact from the Part D redesign in 2025? - Management indicated that there are many moving parts to the Part D redesign, with no specific guidance on direct dollar impact at this time [40][42] Question: Update on patent life for tafamidis? - Management clarified that Vyndaqel and Vyndamax currently have U.S. patent exclusivity through the end of this year, with potential extensions being pursued [51][68] Question: Expectations for gross margin for the full year? - Management expects gross margin to remain above 70% for the year, with fluctuations primarily due to product mix [110][111] Question: Update on Abrysvo contracting efforts? - Management stated that contracting conversations for Abrysvo are progressing, with more updates expected later [126][127] Question: Upcoming pipeline readouts that excite management? - Management highlighted potential approvals for Marstacimab and DMD gene therapy as significant upcoming events [133][134]

Key TakeawaysPfizer's stock rose Wednesday after first-quarter revenue and earnings fell less than expected.Revenue for Pfizer from non-COVID-related products offset some of the waning demand for vaccines and treatments against the virus.The company affirmed its revenue guidance for the year and boosted its profit outlook after committing to savings measures that could yield about $4 billion. Pfizer (PFE) shares rose Wednesday after first-quarter earnings and revenue fell less than expected, with the declin ...